Newspaper Publication
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cohance Lifesciences Ltd (formerly Suven Pharmaceuticals) has published its audited financial results for Q4 and full year FY26 in newspapers as per SEBI LODR requirements. Standalone total income for FY26 declined to ₹2,030.50 Cr from ₹2,504.43 Cr in FY25. Net profit after tax dropped significantly to ₹228.71 Cr from ₹491.18 Cr — roughly a 53% decline. Q4 standalone revenue was ₹567.55 Cr versus ₹768.57 Cr in Q4 FY25, and Q4 net profit fell to ₹34.56 Cr from ₹122.77 Cr. Consolidated figures also show similar declining trends. The company published results in Business Standard (English) and Lokmat (Marathi) on May 13, 2026. The filing was signed by Sisir K. Mishra, Company Secretary.
The company has reported a significant year-on-year decline in both revenue and profitability for FY26, which is a cause for concern for investors. The substantial drop in net profit may put pressure on the stock price in the near term.